ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1513

Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019
Abstract Number: 2592

Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 0666

Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Abstract Number: 0752

Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Abstract Number: 1243

Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Abstract Number: 1149

Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Abstract Number: 0969

Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study
Abstract Number: 0831

Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Abstract Number: 1677

Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Abstract Number: 2154

Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Abstract Number: 0542

Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
Abstract Number: 0574

Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
Abstract Number: 2243

Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis
Abstract Number: 1045

Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis
Abstract Number: 2066

Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].